Good Afternoon Everyone,

My name is Cole and I am very excited to learn all about this industry. I am truly inspired by the work that is done in the field, but I still have much to learn. Thank you for the acceptance into this group and I look forward to meeting like-minded industry leaders here!

Cheers!

-Cole Cipriani
Staffing Consultant
Beacon Hill Life Sciences

The inaugural virtual Prostate Cancer Drug Development Summit is the first dedicated conference for large pharma, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery, translation, and clinical development of safe and effective treatments for prostate cancer.

Here's a sneak peek of crucial topics to be addressed and you shouldn't miss:
• Exploring the role of immunotherapy for the treatment of prostate cancer
• Bringing theranostics to prostate cancer
• Optimizing strategies for overcoming the immunosuppressive prostate tumor microenvironment
• Assessing opportunities and challenges for T-cell directed therapies in prostate cancer
• Examining next-generation small molecule inhibitors, degraders of androgen receptor (AR) and AR-splice variants

Join 80+ thought-leaders with the likes of Amgen, Bristol-Myers Squibb, Novartis, Noxopharm, and many more, and leave this meeting with the latest scientific insights from renowned Urologists/Oncologists striving to advance safe and effective therapeutic breakthroughs to patients in need.

For more information visit: www.prostatecancer-drugdevelopment.com

Based on real examples, reflect on the challenges encountered and solutions developed to detect NAb for immunogenicity assessment with Dr.Regina Bruyns and Sripriya Jaganathan on April 20 at 4pm CET.
In this 45-minute interactive event, we will address the following points:
• Neutralizing anti-drug antibodies
• Competitive ligand binding assay formats to detect NAb
• Challenges in NAb detection
• Approaches to minimize drug interference in NAb assays
• Live Q & A session
Join us, it's 100% FREE.


REGISTER HERE: https://zoom.us/webinar/register/2916177964737/WN__ae_VvMPT0yxvuMtOZNhvQ

Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency
Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December.

Full details: https://www.roche.com/media/releases/med-cor-2018-10-15.htm?utm_source=T&utm_medium=E

Roche today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO Tumor Tissue Targeted Kit, Expanded Kit and Surveillance Kit.[1] The kits, which detect all four mutation classes in solid tumours, complement Roche’s NGS ctDNA kits for oncology research. The AVENIO research-use-only (RUO) portfolio of ready-to-use kits provides reagents and software needed for labs to determine the genomic characteristics of solid tumours through a single DNA workflow.
“With the launch of these innovative assays we are pleased to further empower researchers around the world to continue to advance personalised oncology,” said Michael Heuer, CEO Roche Diagnostics. “These three ready-to-use AVENIO Tumor Tissue Analysis Kits enable researchers by providing relevant panel content that cover all four mutation classes to support the wide variety of cases that require genomic profiling, and complement the previously launched AVENIO ctDNA assays for liquid biopsy.”

Read more: http://bit.ly/2EiUTbA

Scorpion venom supplier

The study published in JCI finds that prostate cancer drug byproduct can fuel cancer cells

Which are the organizations in Canada pursuing Preclinical oncology drug discovery and development?